Active	Status	Sponsor type	Region	Phase	Filter
4 Active 4 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Roberts, Michael
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer	Terminated	3	20	Canada, US, RoW	Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo	Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)	High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	09/23	09/23
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Active, not recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	12/25	07/26
NCT05984186: Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline	Completed	N/A	15	US	High Velocity Therapy	Vapotherm, Inc., Auburn University	Dyspnea, Lactic Acidosis, Muscle, Breathlessness, Exercise, Recovery	07/23	12/23
NCT06537232: Greens-Based Crossover Trial to Improve Epigenetic Aging in Adults	Active, not recruiting	N/A	20	US	Greens-based Supplement	Auburn University, Brickhouse Nutrition	Aging	12/24	03/25